Nothing Special   »   [go: up one dir, main page]

EA201791095A1 - Способ лечения рака - Google Patents

Способ лечения рака

Info

Publication number
EA201791095A1
EA201791095A1 EA201791095A EA201791095A EA201791095A1 EA 201791095 A1 EA201791095 A1 EA 201791095A1 EA 201791095 A EA201791095 A EA 201791095A EA 201791095 A EA201791095 A EA 201791095A EA 201791095 A1 EA201791095 A1 EA 201791095A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment method
cancer treatment
inhibitor
ezh2
methods
Prior art date
Application number
EA201791095A
Other languages
English (en)
Inventor
Хайке Кайльхак
Бретт Труитт
Юта Сузуки
Цукаса Мурасе
Футоси Сиката
Original Assignee
Эпизайм, Инк.
ЭИСАИ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк., ЭИСАИ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. filed Critical Эпизайм, Инк.
Publication of EA201791095A1 publication Critical patent/EA201791095A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретение относится к фармацевтическим композициям, содержащим ингибитор(ы) гистонметилтрансферазы EZH2 человека, и способам терапии рака с применением ингибитора(ов) EZH2.
EA201791095A 2014-11-17 2015-11-17 Способ лечения рака EA201791095A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Publications (1)

Publication Number Publication Date
EA201791095A1 true EA201791095A1 (ru) 2017-10-31

Family

ID=56014476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791095A EA201791095A1 (ru) 2014-11-17 2015-11-17 Способ лечения рака

Country Status (21)

Country Link
US (2) US10786511B2 (ru)
EP (2) EP4272742A1 (ru)
JP (3) JP6829684B2 (ru)
KR (3) KR20240035908A (ru)
CN (2) CN116650500A (ru)
AU (3) AU2015350108B2 (ru)
BR (1) BR112017010166A2 (ru)
CA (1) CA2967664A1 (ru)
DK (1) DK3220916T3 (ru)
EA (1) EA201791095A1 (ru)
ES (1) ES2947819T3 (ru)
FI (1) FI3220916T3 (ru)
HU (1) HUE062159T2 (ru)
IL (3) IL296080B2 (ru)
LT (1) LT3220916T (ru)
MX (2) MX2017006089A (ru)
PL (1) PL3220916T3 (ru)
PT (1) PT3220916T (ru)
SG (1) SG11201703806XA (ru)
SI (1) SI3220916T1 (ru)
WO (1) WO2016081523A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691079A1 (ru) 2013-12-06 2017-03-31 Эпизим, Инк. Комбинированная терапия для лечения онкологического заболевания
CN106999498B (zh) 2014-06-17 2021-06-08 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
DK3220916T3 (da) 2014-11-17 2023-06-26 Epizyme Inc Fremgangsmåde til behandling af cancer med n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamid
EP3285773A4 (en) 2015-04-20 2019-04-10 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
EP3307713A4 (en) 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
EP3341080A4 (en) 2015-08-24 2019-03-20 Epizyme Inc METHOD FOR THE TREATMENT OF CANCER
AU2017211331A1 (en) 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
WO2017218953A1 (en) 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
KR20190105602A (ko) 2017-01-19 2019-09-17 다이이찌 산쿄 가부시키가이샤 Htlv-1 관련 척수증을 치료하는 것에 사용하기 위한 의약 조성물
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline salt of hydrobromide of ezh2 inhibitor, its preparation and effective pharmaceutical composition for cancer treatment
JP2022167451A (ja) 2021-04-23 2022-11-04 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012097222A1 (en) * 2011-01-14 2012-07-19 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
KR102453519B1 (ko) * 2012-03-12 2022-10-11 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
CA2870010C (en) * 2012-04-13 2023-02-21 Epizyme, Inc. Combination therapy for treating cancer
CN104603130B (zh) 2012-04-13 2018-04-27 Epizyme股份有限公司 人类组蛋白甲基转移酶ezh2抑制剂的盐形式
SI2908823T1 (sl) * 2012-10-15 2019-11-29 Epizyme Inc Postopki zdravljenja raka
TWI588131B (zh) 2012-10-15 2017-06-21 雅酶股份有限公司 經取代苯化合物
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
AU2013361079B2 (en) 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014100646A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
WO2014172044A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
FI3057962T3 (fi) * 2013-10-16 2023-11-03 Epizyme Inc Hydrokloridisuolamuoto ezh2-estoon
AU2014337121A1 (en) 2013-10-18 2016-04-14 Epizyme, Inc. Method of treating cancer
EA201691079A1 (ru) 2013-12-06 2017-03-31 Эпизим, Инк. Комбинированная терапия для лечения онкологического заболевания
CN106999498B (zh) * 2014-06-17 2021-06-08 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
AU2015331729A1 (en) 2014-10-16 2017-04-13 Epizyme, Inc. Method for treating cancer
DK3220916T3 (da) 2014-11-17 2023-06-26 Epizyme Inc Fremgangsmåde til behandling af cancer med n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamid
EP3307713A4 (en) * 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
WO2017218953A1 (en) * 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer

Also Published As

Publication number Publication date
IL252182B (en) 2022-10-01
LT3220916T (lt) 2023-07-25
ES2947819T3 (es) 2023-08-21
IL304252A (en) 2023-09-01
IL252182B2 (en) 2023-02-01
MX2021006734A (es) 2021-07-02
JP2023062189A (ja) 2023-05-02
EP4272742A1 (en) 2023-11-08
CA2967664A1 (en) 2016-05-26
NZ768247A (en) 2024-05-31
SG11201703806XA (en) 2017-06-29
CN107249591A (zh) 2017-10-13
US20210060030A1 (en) 2021-03-04
KR20240035908A (ko) 2024-03-18
EP3220916B1 (en) 2023-04-19
KR20210156840A (ko) 2021-12-27
KR102338802B1 (ko) 2021-12-14
AU2015350108B2 (en) 2021-04-08
KR102644844B1 (ko) 2024-03-07
AU2015350108A1 (en) 2017-05-25
JP2021073241A (ja) 2021-05-13
US20170360797A1 (en) 2017-12-21
NZ731696A (en) 2024-03-22
CN116650500A (zh) 2023-08-29
BR112017010166A2 (pt) 2018-02-14
FI3220916T3 (fi) 2023-06-19
IL296080B1 (en) 2023-08-01
JP6829684B2 (ja) 2021-02-10
JP2017537899A (ja) 2017-12-21
HUE062159T2 (hu) 2023-10-28
KR20170103768A (ko) 2017-09-13
AU2021204706A1 (en) 2021-07-29
US10786511B2 (en) 2020-09-29
MX2017006089A (es) 2017-12-11
AU2021204706B2 (en) 2023-11-23
DK3220916T3 (da) 2023-06-26
PT3220916T (pt) 2023-06-26
CN107249591B (zh) 2024-01-30
SI3220916T1 (sl) 2023-09-29
JP7485810B2 (ja) 2024-05-16
EP3220916A4 (en) 2018-07-11
PL3220916T3 (pl) 2023-08-14
AU2024201171A1 (en) 2024-03-14
IL296080A (en) 2022-11-01
WO2016081523A1 (en) 2016-05-26
IL296080B2 (en) 2023-12-01
EP3220916A1 (en) 2017-09-27
IL252182A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
EA201791095A1 (ru) Способ лечения рака
EA201890567A1 (ru) Способ лечения рака
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201591599A1 (ru) Ингибиторы ido
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
ZA201807438B (en) Methods of treating ocular conditions
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
ZA201703467B (en) Methods of treating ocular conditions
EA201691896A1 (ru) Соединения и способы их применения